CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 197 enrolled
Drug / intervention
Liafensine +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT05113771
NCT05113771Phase 2Completed
CompareCT.gov

A Biomarker-Guided, Randomized, Double-Blind, Placebo-Controlled Efficacy and Safety Study of Liafensine in Patients With Treatment-Resistant Depression

Denovo Biopharma LLC·interventional·Posted Nov 9, 2021·Updated May 15, 2025

In Brief

A Phase 2 clinical trial evaluating Liafensine and Placebo for Treatment Resistant Depression. Completed, enrolled 197 participants across 45 sites in 2 countries.

Detailed Summary

This study was conducted as a randomized, double-blind, placebo-controlled, multi-center Phase 2b study. Approximately 180 subjects with treatment resistant depression who meet all eligibility criteria will be enrolled. The primary endpoint is to demonstrate liafensine is superior to placebo in DGM4 positive patients with TRD.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsTreatment Resistant Depression
CountriesCanada, United States
Collaborators--

Timeline

Phase 2CompletedFinished
20222023202420252026
First PostedNov 9, 2021
Enrollment StartJun 29, 2022
Primary CompletionFeb 6, 2024
Study CompletionMar 5, 2024
TodayJul 2, 2026
Enrollment to primary: 1.6 yearsPosted 4.6 years ago

Interventions

Liafensinedrug

Liafensine

Placebodrug

Placebo